Tag: Vascular Therapies

Vascular Therapies Announces Positive Preliminary Clinical Results from its AV Fistula Trials in Patients with Kidney Disease

CRESSKILL, N.J., Sept. 9, 2019 /PRNewswire/ — Vascular Therapies, a clinical stage biotechnology company, is developing Sirogen™, a proprietary sirolimus formulation for intraoperative local, perivascular drug delivery focused on improving vascular access outcomes in patients with kidney disease.  Daniel G. Clair, MD, vascular surgeon and Chairman of the Department of Surgery at Palmetto Health-USC […]

Vascular Therapies Appoints John McDermott as Chief Executive Officer

CRESSKILL, N.J., Jan. 9, 2019 /PRNewswire/ — Vascular Therapies, a biotechnology company focused on improving outcomes for patients with advanced kidney disease, today announced the appointment of John McDermott as the Company’s Chief Executive Officer. Bob Croce, Chairman of the Board of Directors of Vascular Therapies, Inc. commented, “We are very pleased to welcome John […]

Vascular Therapies Announces Preliminary Results From its Phase III AV Fistula Study

CRESSKILL, N.J., Nov. 9, 2017 /PRNewswire/ — An innovative, investigational treatment approach is showing the potential to address an important, unresolved problem encountered by patients with kidney failure on dialysis. At the recent annual meeting of the American Society of Nephrology (ASN), Vascular Therapies, Inc. presented preliminary results relating to […]